Director, CEO · Roivant Sciences Ltd. · Common Shares
Side
SELL
Value
$8.45M
Shares
289.8K
Price
$29.16
Executed
Apr 16, 2026
Disclosed
Apr 20, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Apr 16 executedApr 20, 2026 disclosed
ROIV · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering+5 / 15
1 other actor traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Gline Matthew filed this Form 4 reporting a open-market sale of ROIV on Apr 16, 2026. It became public on Apr 20, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, CEO
Gline Matthewcik:0001750094
Issuer
Roivant Sciences Ltd.cik:0001635088
Revision history · 0
No field has changed since this record was first ingested.
